drugset / Trial / NCT00176332

Impact of Rosuvastatin on Endothelial Function and Inflammation in Patients With Chronic Heart Failure

NCT00176332

Phase 2 Completed 40 enrolled University of Leipzig AstraZeneca · collab
RandomizedSingle-groupDouble-blindTreatment

Summary

Statin therapy has been shown to efficiently reduce mortality in patients with coronary artery disease and myocardial infarction, partially as a result of the lipid-lowering properties of statins. However, especially the pleiotropic effects of statins, e.g. their anti-inflammatory and anti-oxidative properties, might be of interest in the treatment of patients with chronic heart failure that are limited in their exercise capacity due to alterations of the skeletal muscle and peripheral endothelial dysfunction. Aim of this trial is therefore to assess the effects of three months of rosuvastatin treatment on markers of inflammation and oxidative stress in the skeletal muscle and the blood, on postnatal vasculogenesis, and endothelial function of the radial artery in patients with severe chronic heart failure.

Timeline

Start
2004-03
Primary completion
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosuvastatin Small molecule

Indications